REGENXBIO Management

Management criteria checks 2/4

REGENXBIO's CEO is Ken Mills, appointed in Mar 2009, has a tenure of 15.17 years. total yearly compensation is $5.92M, comprised of 11.4% salary and 88.6% bonuses, including company stock and options. directly owns 0.56% of the company’s shares, worth €4.29M. The average tenure of the management team and the board of directors is 7.5 years and 7.8 years respectively.

Key information

Ken Mills

Chief executive officer

US$5.9m

Total compensation

CEO salary percentage	11.4%
CEO tenure	15.2yrs
CEO ownership	0.6%
Management average tenure	7.5yrs
Board average tenure	7.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Ken Mills's remuneration changed compared to REGENXBIO's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	US$6m	US$677k	-US$263m
Sep 30 2023	n/a	n/a	-US$261m
Jun 30 2023	n/a	n/a	-US$274m
Mar 31 2023	n/a	n/a	-US$270m
Dec 31 2022	US$6m	US$651k	-US$280m
Sep 30 2022	n/a	n/a	US$74m
Jun 30 2022	n/a	n/a	US$91m
Mar 31 2022	n/a	n/a	US$101m
Dec 31 2021	US$9m	US$632k	US$128m
Sep 30 2021	n/a	n/a	-US$212m
Jun 30 2021	n/a	n/a	-US$145m
Mar 31 2021	n/a	n/a	-US$121m
Dec 31 2020	US$8m	US$613k	-US$111m
Sep 30 2020	n/a	n/a	-US$91m
Jun 30 2020	n/a	n/a	-US$135m
Mar 31 2020	n/a	n/a	-US$103m
Dec 31 2019	US$6m	US$596k	-US$95m
Sep 30 2019	n/a	n/a	-US$64m
Jun 30 2019	n/a	n/a	-US$49m
Mar 31 2019	n/a	n/a	-US$37m
Dec 31 2018	US$5m	US$546k	US$100m
Sep 30 2018	n/a	n/a	US$80m
Jun 30 2018	n/a	n/a	US$78m
Mar 31 2018	n/a	n/a	US$53m
Dec 31 2017	US$3m	US$530k	-US$73m

Compensation vs Market: Ken's total compensation ($USD5.92M) is above average for companies of similar size in the German market ($USD1.18M).

Compensation vs Earnings: Ken's compensation has increased whilst the company is unprofitable.

CEO

Ken Mills (48 yo)

15.2yrs

Tenure

US$5,916,712

Compensation

Mr. Kenneth T. Mills, also known as Ken, has been the Chief Executive Officer, President and Director at REGENXBIO Inc., (formerly REGENX Biosciences, LLC) since March 2009. Mr. Mills was a Partner at FOXK...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Kenneth Mills	President	15.2yrs	US$5.92m	0.56% $ 4.3m
Vittal Vasista	Executive VP & CFO	14.8yrs	US$2.62m	0.38% $ 2.9m
Curran Simpson	Executive VP & COO	no data	US$2.95m	0.051% $ 392.5k
Olivier Danos	Executive VP & Chief Scientific Officer	7.2yrs	US$2.99m	0.059% $ 448.6k
Stephen Pakola	Executive VP & Chief Medical Officer	5.1yrs	US$3.31m	0% $ 0
Patrick Christmas	Executive VP & Chief Legal Officer	7.8yrs	US$3.44m	0.046% $ 356.3k
Shiva Fritsch	Chief Communications & People Officer	6.6yrs	no data	no data
Laura Coruzzi	Executive Vice President of Intellectual Property	8yrs	no data	no data
Ram Palanki	Executive VP of Commercial Strategy & Operations	5.8yrs	no data	no data

7.5yrs

Average Tenure

54.5yo

Average Age

Experienced Management: RB0's management team is seasoned and experienced (7.5 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Kenneth Mills	President	15.2yrs	US$5.92m	0.56% $ 4.3m
David Stump	Independent Director	8.6yrs	US$339.98k	0.0061% $ 47.1k
George Migausky	Independent Director	2.7yrs	US$339.98k	0.0061% $ 47.1k
Argeris Karabelas	Lead Independent Director	9yrs	US$352.48k	0.0061% $ 47.1k
Inder Verma	Member of Scientific Advisor	no data	no data	no data
Allan Fox	Chairman of the Board	15.3yrs	US$354.98k	6.45% $ 49.5m
Judith Swain	Member of Scientific Advisor	no data	no data	no data
Alexandra Glucksmann	Independent Director	6yrs	US$327.48k	0.0061% $ 47.1k
Daniel Tassé	Independent Director	7.8yrs	US$334.98k	0.0061% $ 47.1k
Jean Bennett	Independent Director	2.7yrs	US$324.98k	0.0061% $ 47.1k
Jennifer Zachary	Independent Director	1.9yrs	US$329.98k	0.0041% $ 31.4k

7.8yrs

Average Tenure

69yo

Average Age

Experienced Board: RB0's board of directors are considered experienced (7.8 years average tenure).

REGENXBIO Management

Management criteria checks 2/4

Key information

Recent management updates

REGENXBIO Inc., Annual General Meeting, May 31, 2024

REGENXBIO Inc. Announces Executive Promotions

Executive VP & Chief Financial Officer recently sold €144k worth of stock

Regenxbio Inc. Appoints Jennifer Zachary to its Board of Directors

REGENXBIO Inc., Annual General Meeting, Jun 03, 2022

Chairman of the Board recently sold €1.9m worth of stock

Recent updates

REGENXBIO Inc., Annual General Meeting, May 31, 2024

REGENXBIO Inc. Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD

REGENXBIO Inc. has filed a Follow-on Equity Offering in the amount of $125 million.

REGENXBIO Inc. has completed a Follow-on Equity Offering in the amount of $140.000848 million.

REGENXBIO Inc. Announces New Interim Safety and Efficacy Data from Duchenne Trial

New minor risk - Shareholder dilution

Full year 2023 earnings released: US$6.03 loss per share (vs US$6.50 loss in FY 2022)

New major risk - Financial position

REGENXBIO Inc. Announces Pivotal Trial of RGX-121 for the Treatment of MPS II Achieves Primary Endpoint

REGENXBIO Inc. Announces Positive Interim Data from Phase II AAVIATE® Trial of ABBV-RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery

New major risk - Financial position

REGENXBIO Inc. Announces Dose Escalation in AFFINITY Duchenne®? Trial

Third quarter 2023 earnings released: US$1.41 loss per share (vs US$1.75 loss in 3Q 2022)

REGENXBIO Inc. Presents Positive One Year Data from Phase II ALTUDE®? Trial of ABBV-RGX-314 for Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery

New minor risk - Share price stability

Vitreous Retina Macula Consultants of New York Announces Participation in Wet AMD Study in Collaboration with Regenxbio

REGENXBIO Inc. Announces Additional Interim Safety Data and Initial Efficacy Data from the Phase I/II AFFINITY Duchenne Trial of RGX-202

REGENXBIO Inc. Announces Initial Clinical Data from First Pediatric CLN2 Patient Dosed with RGX-181

Second quarter 2023 earnings released: US$1.66 loss per share (vs US$1.58 loss in 2Q 2022)

REGENXBIO Highlights AAV Pipeline with Interim Results from Retinal and Duchenne Programs at its Virtual Investor Day on July 11, 2023

First quarter 2023 earnings released: US$1.54 loss per share (vs US$1.79 loss in 1Q 2022)

Full year 2022 earnings released: US$6.50 loss per share (vs US$3.01 profit in FY 2021)

REGENXBIO Inc. Presents Interim Data from Phase II Bridging Study Evaluating the Clinical Performance of RGX-314 Using the NAVXpress™ Manufacturing Platform Process

REGENXBIO Inc. Announces Phase I/II Trial of RGX-202, a Novel Gene Therapy Candidate for Duchenne Muscular Dystrophy, Is Active and Recruiting Patients

REGENXBIO Inc. Announces Executive Promotions

REGENXBIO Inc. Reports Update on Advancement of Programs for CLN2 Disease

Regenxbio Announces Completion of Dosing in the Phase I/Ii Trial of Rgx-111 for the Treatment of Severe Mps I

Investor sentiment deteriorated over the past week

Third quarter 2022 earnings released: US$1.75 loss per share (vs US$1.37 loss in 3Q 2021)

REGENXBIO Inc. Presents Positive Interim Data from and the Expansion of Phase II ALTITUDE(R) Trial of Rgx-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery

Investor sentiment improved over the past week

Regenxbio Inc. Announces Additional Positive Interim Data from the Phase I/Ii/Iii Campsiite™ Trial of Rgx-121 for the Treatment of Patients Up to 5 Years Old Diagnosed with Mucopolysaccharidosis Type Ii (Mps Ii), Also Known as Hunter Syndrome

Investor sentiment deteriorated over the past week

Second quarter 2022 earnings released: US$1.58 loss per share (vs US$1.36 loss in 2Q 2021)

REGENXBIO Announces Intention to File a Biologics License Application Using the Accelerated Approval Pathway for RGX-121, an AAV Therapeutic for the Treatment of MPS II

Executive VP & Chief Financial Officer recently sold €144k worth of stock

Investor sentiment improved over the past week

REGENXBIO Inc. Announces Enrollment Complete in Cohort 5 of Phase II AAVIATE® Trial

Investor sentiment improved over the past week

Regenxbio Inc. Appoints Jennifer Zachary to its Board of Directors

Investor sentiment deteriorated over the past week

First quarter 2022 earnings released: US$1.79 loss per share (vs US$1.20 loss in 1Q 2021)

REGENXBIO Inc., Annual General Meeting, Jun 03, 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

REGENXBIO Presents Positive Interim Data from Phase II ALTITUDE Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery

REGENXBIO Inc. Presents Additional Positive Interim Data from Phase I/II Trial of RGX-121 for the Treatment of MPS II (Hunter Syndrome) at 18th Annual WORLDSymposium™ 2022

REGENXBIO Inc. Announces Initiation of Second Pivotal Trial in RGX-314 Clinical Program for the Treatment of Wet AMD Using Subretinal Delivery

REGENXBIO Inc. Announces FDA Clearance of IND for Clinical Trial of RGX-202, a Novel Gene Therapy Candidate for Duchenne Muscular Dystrophy

REGENXBIO Inc. Announces Orphan Drug Designation Granted to RGX-202, A Novel Gene Therapy Candidate for the Treatment of Duchenne Muscular Dystrophy

Third quarter 2021 earnings released: US$1.37 loss per share (vs US$0.23 profit in 3Q 2020)

REGENXBIO Inc. Announces RGX-314 Data Presentations at Retina Society 54th Annual Scientific Meeting

Chairman of the Board recently sold €1.9m worth of stock

Independent Director Luke Beshar has left the company

Second quarter 2021 earnings released: US$1.36 loss per share (vs US$0.91 loss in 2Q 2020)

REGENXBIO Presents Additional Positive Interim Data from Phase I/II Trial of RGX-121 for the Treatment of MPS II (Hunter Syndrome) at American Society of Gene and Cell Therapy's 24th Annual Meeting

First quarter 2021 earnings released: US$1.20 loss per share (vs US$1.08 loss in 1Q 2020)

Full year 2020 earnings released: US$2.98 loss per share (vs US$2.58 loss in FY 2019)

Revenue misses expectations

REGENXBIO Announces Additional Positive Interim Phase I/IIa and Long-Term Follow-Up Data of RGX-314 for the Treatment of Wet AMD

REGENXBIO Presents Additional Positive Interim Data from Phase I/II Trial of RGX-121 for the Treatment of MPS II (Hunter Syndrome) at 17th Annual WORLDSymposium™ 2021

New 90-day high: €40.70

Regenxbio Inc. Announces Update on RGX-314 and Pivotal Program for the Treatment of Wet AMD

REGENXBIO Announces Dosing of First Patient in Phase II ALTITUDE™ Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery

New 90-day high: €30.75

REGENXBIO Announces Dosing of First Patient in Phase I/II Trial of RGX-111 for the Treatment of Mucopolysaccharidosis Type I

New 90-day high: €28.26

REGENXBIO Appoints Olivier Danos to its Board of Directors

Third quarter 2020 earnings released: EPS US$0.23

Revenue beats expectations